Information Provided By:
Fly News Breaks for February 26, 2020
NVS, REGN
Feb 26, 2020 | 08:50 EDT
As reported previously, Canaccord analyst John Newman upgraded Regeneron (REGN) to Buy from Hold. The analyst noted its competition decreased when the ASRS warned about 14 cases of vasculitis in patients that received Novartis's (NVS) Beovu. The analyst noted the report should reduce the EYLEA competitive concerns in the wet AMD space. Newman raised his price target to $550 from $409 on Regeneron shares.
News For REGN;NVS From the Last 2 Days
NVS
Apr 24, 2024 | 07:26 EDT
TD Cowen analyst Yaron Werber raised the firm's price target on BeiGene (BGNE) to $236 from $235 and keeps a Buy rating on the shares. The firm updated its model to reflect lower collaborative revenue given termination of Novartis (NVS) agreement for tisle in Sep 2023.
REGN
NVS
NVS
NVS
NVS
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.